Table Info

Table 3.

General characteristics of studies on the role of NLR in differentiating between different types of tCa

Reference	Sample size	Study design	Year of publication	Country	Histopathology	Cut off value of NLR	Seminomatous tCa	Outcome
Arıman and Merder [27]	152	Retrospective cohort	2021	Turkey	tCa	2.39	52.60%	There was no statistically significant difference between cases with seminoma and non-seminomatous tCa.
Jankovich et al. [38]	103	Retrospective cohort	2017	Slovakia	TGCT	4	39.80%	There was no statistically significant difference in NLR level between patients with seminomas and non-seminomatous tCa.
Kopru et al. [42]	80	Retrospective cohort	2019	Turkey	tCa	-	51.51%	No statistically significant difference, was found in NLR of patients with seminomas and non-seminomatous tCa groups.
Köşeci et al. [43]	72	Retrospective cohort	2021	Turkey	TGCT	2.5	43.00%	NLR level wasn’t significantly different between seminomas and non-seminomatous tCa groups.
Olcucu et al. [44]	99	Retrospective cohort	2020	Turkey	TGCT	3.21	45.45%	There was no significant correlation between NLR and different types of tCa.
Horsanali et al. [36]	128	Retrospective cohort	2017	Turkey	TGCT	3.72	44.80%	There was statistically significant difference in NLR between different tumor histopathology.

tCa: testicular cancer; TGCT: testicular germ cell tumor; NLR: neutrophil to lymphocyte ratio

Declarations

Author contributions

SS: Conceptualization. SB: Investigation, Writing—original draft. SK: Conceptualization, Writing—review & editing. AS: Investigation. AC: Investigation. DK: Writing—original draft. MK: Writing—review & editing. AG: Writing—review & editing. BLW: Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Datasets are available on request.

Funding

Not applicable.

Copyright

References

Mjaess G, Chebel R, Karam A, Moussa I, Pretot D, Abi Tayeh G, et al. Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in urological tumors: an umbrella review of evidence from systematic reviews and meta-analyses. Acta Oncol. 2021;60:704–13. [DOI] [PubMed]

Tan YG, Sia J, Huang HH, Lau WKO. Neutrophil-to-lymphocyte ratio independently predicts advanced pathological staging and poorer survival outcomes in testicular cancer. Investig Clin Urol. 2019;60:176–83. [DOI]

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403. [DOI] [PubMed]

Imamoglu GI, Eren T, Baylan B, Karacın C. May High Levels of Systemic Immune-Inflammation Index and Hematologic Inflammation Markers Suggest a Further Stage in Testicular Tumours? Urol Int. 2019;103:303–10. [DOI] [PubMed]

Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23:50. [DOI] [PubMed] [PMC]

Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51:27–41. [DOI] [PubMed] [PMC]

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99. [DOI] [PubMed] [PMC]

Ohno Y. Role of systemic inflammatory response markers in urological malignancy. Int J Urol. 2019;26:31–47. [DOI] [PubMed]

Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 2012;1:1223–5. [DOI] [PubMed] [PMC]

10.

Paulsen Ø, Laird B, Aass N, Lea T, Fayers P, Kaasa S, et al. The relationship between pro-inflammatory cytokines and pain, appetite and fatigue in patients with advanced cancer. PLoS One. 2017;12:e0177620. [DOI] [PubMed] [PMC]

11.

Guo J, Chen S, Chen Y, Li S, Xu D. Combination of CRP and NLR: a better predictor of postoperative survival in patients with gastric cancer. Cancer Manag Res. 2018;10:315–21. [DOI] [PubMed] [PMC]

12.

Hwang KT, Chung JK, Roh EY, Kim J, Oh S, Kim YA, et al. Prognostic Influence of Preoperative Fibrinogen to Albumin Ratio for Breast Cancer. J Breast Cancer. 2017;20:254–63. [DOI] [PubMed] [PMC]

13.

Chen L, Kong X, Yan C, Fang Y, Wang J. The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer. Onco Targets Ther. 2020;13:1397–412. [DOI] [PubMed] [PMC]

14.

Lin JX, Tang YH, Wang JB, Lu J, Chen QY, Cao LL, et al. Blood parameters score predicts long-term outcomes in stage II-III gastric cancer patients. World J Gastroenterol. 2019;25:6258–72. [DOI] [PubMed] [PMC]

15.

Khunger M, Patil PD, Khunger A, Li M, Hu B, Rakshit S, et al. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PLoS One. 2018;13:e0197743. [DOI] [PubMed] [PMC]

16.

Mehrabi Z, Salimi M, Niknam K, Mohammadi F, Mamaghani HJ, Sasani MR, et al. Sinoorbital Mucormycosis Associated with Corticosteroid Therapy in COVID-19 Infection. Case Rep Ophthalmol Med. 2021;2021:9745701. [DOI] [PubMed] [PMC]

17.

Jahangiri S, Mousavi SH, Hatamnejad MR, Salimi M, Bazrafshan H. Prevalence of non-steroidal anti-inflammatory drugs (NSAIDs) use in patients with hypertensive crisis. Health Sci Rep. 2022;5:e483. [DOI] [PubMed] [PMC]

18.

Sheikhesmaeili F, Salimi M, Salimi A, Nikandish N, Jahangiri S, Mamaghani HJ, et al. Comparison of Serologic Celiac Disease in Patients with Hypothyroidism and Healthy Controls: A Case-Control Study. J Bio Res. 2021;3:15–21. [DOI]

19.

Yang S, Zhao K, Ding X, Jiang H, Lu H. Prognostic Significance of Hematological Markers for Patients with Nasopharyngeal Carcinoma: A Meta-analysis. J Cancer. 2019;10:2568–77. [DOI] [PubMed] [PMC]

20.

Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, et al. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pac J Cancer Prev. 2019;20:863–8. [DOI] [PubMed] [PMC]

21.

Kumarasamy C, Sabarimurugan S, Madurantakam RM, Lakhotiya K, Samiappan S, Baxi S, et al. Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e14834. [DOI] [PubMed] [PMC]

22.

Li YX, Chang JY, He MY, Wang HR, Luo DQ, Li FH, et al. Neutrophil-to-Lymphocyte Ratio (NLR) and Monocyte-to-Lymphocyte Ratio (MLR) Predict Clinical Outcome in Patients with Stage IIB Cervical Cancer. J Oncol. 2021;2021:2939162. [DOI] [PubMed] [PMC]

23.

Moghimi N, Faridfar A, Shahriarirad R, Nikandish M, Salimi A, Salimi M. Evaluation of the relationship between vitamin D levels and related serum markers as well as disease activity in patients with rheumatoid arthritis: A cross-sectional study. J Bio Res. 2021;3:1–9. [DOI]

24.

Nematollahi MA, Askarinejad A, Asadollahi A, Salimi M, Moghadami M, Sasannia S, et al. Association and predictive capability of body composition and diabetes mellitus using artificial intelligence: a cohort study. Research Square [Preprint]. 2022 [cited 2023 Nov 28]. Available from: https://europepmc.org/article/PPR/PPR506305

25.

Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122:474–88. [DOI] [PubMed]

26.

Arda E, Arikan G, Akdere H, Akgul M, Yuksel I. Predictive and prognostic impact of preoperative complete blood count based systemic inflammatory markers in testicular cancer. Int Braz J Urol. 2020;46:216–23. [DOI] [PubMed] [PMC]

27.

Arıman A, Merder E. The prognostic importance of neutrophil-to-lymphocyte ratio in testicular cancer. Urologia. 2021;88:200–5. [DOI] [PubMed]

28.

Başer A, Aras B. Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters? Pamukkale Med J. 2021;14:598–603. [DOI]

29.

Bolat D, Aydogdu O, Polat S, Yarimoglu S, Bozkurt IH, Yonguc T, et al. Predictive value of preoperative neutrophil-to-lymphocyte ratio on the prognosis of germ cell testicular tumors. Turkish J Urol. 2017;43:55–61. [DOI]

30.

Çalışkan S, Kaba S, Özsoy E, Koca O, Akyüz M, Öztürk Mİ. The hematological parameters in testicular cancer. J Onco Sci. 2017;3:117–9. [DOI]

31.

Fankhauser CD, Sander S, Roth L, Gross O, Eberli D, Sulser T, et al. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy. Br J Cancer. 2018;118:825–30. [DOI]

32.

Girgin R, Çinar Ö, Bulut E, Akduman B, Çeker G. The Diagnostic Power of the Platelet Mass Index for Testicular Tumours: A Simple Blood Test. Iberoam J Med. 2021;3:257–63. [DOI]

33.

Gokcen K, Dundar G, Gulbahar H, Gokce G, Gultekin EY. Can routine peripheral blood counts like neutrophil-to-lymphocyte ratio be beneficial in prediagnosis of testicular cancer and its stages? J Res Med Sci. 2018;23:64. [DOI] [PubMed] [PMC]

34.

Hamidi N, Alijla A, Gök B, Asil E, Ardıçoğlu A, Atmaca AF. The evaluation of associsation between serum Neutrophil-lymphocyte ratio and pathological prognostic factors, development of metastases during follow in stage I germ cell testicular tumor patients. Van Med J. 2018;25:165–70. [DOI]

35.

Herraiz-Raya L, Moreillo-Vicente L, Martínez-Ruiz J, Agustí-Martínez A, Fernández-Anguita PJ, Esper-Rueda JA, et al. Leukocyte and platelet counts as prognostic values of testicular germ cell tumors. Actas Urológicas Españolas (English Edition). 2019;43:284–92. [DOI]

36.

Horsanali MO, Ozer K, Ozbek E. Peripheral Blood Neutrophil to Lymphocyte Ratio is Positively Correlated with Tumour Aggressiveness in Testicular Cancer. Clin Oncol. 2017;2:1298. [DOI]

37.

Ilktac A, Dogan B, Ersoz C, Akcay M, Akbulut H. The relationship of neutrophil to lymphocyte ratio with testicular cancer. Int Braz J Urol. 2020;46:101–7. [DOI] [PubMed] [PMC]

38.

Jankovich M, Jankovichova T, Ondrus D, Breza J. Neutrophil-to-lymphocyte ratio as a predictor of preoperative tumor staging in testicular germ cell tumors. Bratisl Med J. 2017;118:510–2. [DOI]

39.

Karakaya S, Karadag I, Ates O, Oksuzoglu OBC. Can Neutrophil-To-Lymphocyte Ratio or Platelet-To-Lymphocyte Ratio Predict Chemotherapy Response in Testicular Cancer? EJMI. 2021;5:269–73. [DOI]

40.

Kartal İG, Cimen S, Özenç G, Kokurcan A. The Auxiliary Role of Hematological Parameters in Diagnosing Localized Germ Cell Testicular Tumor. Bull Urooncol. 2020;19:210–4. [DOI]

41.

Kölükçü E, Erdemir F, Kılıç Ş, Firat F, Eti̇kan İ. Testis Tümörlü Hastalarda Tümör Grade İle Preoperatif Nötrofil Lenfosit Oranının İlişkisi. Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi. 2017;9:158–68. Turkish.

42.

Kopru B, Ergin G, Kirac M, Kibar Y. Evaluation of the diagnostic and prognostic value of preoperative inflammatory parameters in testicular tumors. Int J Urol Res. 2019;1:11–4. [DOI]

43.

Köşeci T, Haksöyler V, Karadeniz C, Kaya DM, Dilek O, Sungur A, et al. Efficacy of preoperative neutrophil-to-lymphocyte ratio in determining lymph node metastases in testicular cancer. Cukurova Med J. 2021;46:1070–6. [DOI]

44.

Olcucu MT, Karamik K, Yilmaz K, Okuducu Y, Cakir S, Ates M. Preoperative Inflammation Markers and De Ritis Ratio in Predicting Clinical Presentation and Prognosis of Patients with Testicular Germ Cell Tumors. J Coll Physicians Surg Pak. 2020;30:1041–6. [DOI] [PubMed]

45.

Pęksa R, Kunc M, Popęda M, Piątek M, Bieńkowski M, Żok J, et al. Combined Assessment of Immune Checkpoint Regulator VISTA on Tumor-Associated Immune Cells and Platelet-to-Lymphocyte Ratio Identifies Advanced Germ Cell Tumors with Higher Risk of Unfavorable Outcomes. Cancers (Basel). 2021;13:1750. [DOI] [PubMed] [PMC]

46.

Bauzá Quetglas JL, Tienza Fernández A, Bertolo R, Sabaté Arroyo XA, Guimerà García J, Tubau Vidaña V, et al. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with testicular cancer. Prog Urol. 2020;30:273–80. [DOI] [PubMed]

47.

Şahin A, Toprak T, Kutluhan MA, Vural Y, Ürkmez A, Verit A. Increased neutrophil/lymphocyte ratio in testicular cancer. Archivio Italiano di Urologia e Andrologia. 2019;91. [DOI]

48.

Selvi I, Arık Aİ, Başay MS, Başar H. Oncological Outcomes of Bilateral Testicular Germ Cell Tumors and Evaluation of Prognostic Risk Factors. Bull Urooncol. 2021;20:56–66. [DOI]

49.

Selvi I, Başar H. Additional Preoperative Parameters to Enable the Decision of Partial Orchiectomy in Small Testicular Masses. Bezmialem Sci. 2020;8:48–55. [DOI]

50.

Yang J, Guo X, Hao J, Dong Y, Zhang T, Ma X. The Prognostic Value of Blood-Based Biomarkers in Patients With Testicular Diffuse Large B-Cell Lymphoma. Front Oncol. 2019;9:1392. [DOI] [PubMed] [PMC]

51.

Yigit A, Gorgel SN, Kose O, Ordek E, Yenİ E, Yilmaz Y, et al. Retrospective evaluation of neutrophil to lymphocyte ratio in patients with metastatic testicular cancer. Kuwait Med J. 2018;50:437–41.

52.

Yıldırım ME, Badem H, Karataş ÖF, Çimentepe E. Preoperative Predictive Value of Neuthrophil/Lymphocyte Ratios in Testicular Tumors. Ann Med Res. 2013;20:243–5. [DOI]

53.

Yoshinaga K, Sadahira T, Maruyama Y, Mitsui Y, Iwata T, Wada K, et al. Comparison of inflammation-based prognostic scores as predictors of survival outcomes in patients with germ cell tumors. Investig Clin Urol. 2021;62:47–55. [DOI] [PubMed] [PMC]

54.

Yuksel OH, Verit A, Sahin A, Urkmez A, Uruc F. White blood cell counts and neutrophil to lymphocyte ratio in the diagnosis of testicular cancer: a simple secondary serum tumor marker. Int Braz J Urol. 2016;42:53–9. [DOI] [PubMed] [PMC]

55.

Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68:1054–68. [DOI]

56.

Ley K, Hoffman HM, Kubes P, Cassatella MA, Zychlinsky A, Hedrick CC, et al. Neutrophils: New insights and open questions. Sci Immunol. 2018;3:eaat4579. [DOI] [PubMed]

57.

Bonilla FA, Oettgen HC. Adaptive immunity. J Allergy Clin Immunol. 2010;125:S33–40. [DOI] [PubMed]

58.

Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124. [DOI] [PubMed]